Abilify (aripiprazole) is an atypical antipsychotic manufactured by Otsuka Pharmaceutical Co., Ltd marketed jointly with Bristol-Myers Squibb Canada. It was approved by FDA in November 2002 for the treatment of Schizophrenia. In 2007, FDA approved Aripiprazole for treatment of Unipolar depression as an adjunct with an antidepressant medication. The drug works by either increasing or decreasing dopamine or serotonin levels in the brain when there is an imbalance.
A large number of patients treated with Abilify were reported to develop habit of compulsive gambling and got racked up with large amounts of debts. Other pathological behaviors like excessive eating, excessive shopping and Hypersexuality is also noted who started using or increased dosage of Abilify.
Young patients with depression and elderly patients with dementia consuming Abilify are found to be at a high risk of suicidal thoughts or actions. It also increases risk of developing diabetes.